Thrivent Financial for Lutherans Buys 425,061 Shares of Repligen Co. (NASDAQ:RGEN)

Thrivent Financial for Lutherans raised its stake in Repligen Co. (NASDAQ:RGEN) by 240.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 601,829 shares of the biotechnology company’s stock after acquiring an additional 425,061 shares during the quarter. Thrivent Financial for Lutherans owned about 1.08% of Repligen worth $75,866,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Evoke Wealth LLC bought a new position in shares of Repligen during the fourth quarter worth approximately $1,955,000. Norden Group LLC increased its position in Repligen by 1,711.6% during the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after buying an additional 36,663 shares during the period. Artemis Investment Management LLP lifted its holdings in shares of Repligen by 33.8% during the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after buying an additional 42,380 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after acquiring an additional 6,705 shares during the period. Finally, Congress Asset Management Co. MA grew its stake in shares of Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock valued at $16,187,000 after acquiring an additional 11,213 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Trading Down 1.9 %

Shares of RGEN stock opened at $142.97 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a market cap of $7.99 billion, a PE ratio of 571.88, a P/E/G ratio of 4.14 and a beta of 0.94. The stock’s fifty day moving average price is $147.30 and its two-hundred day moving average price is $155.25.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 earnings per share. Equities analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Royal Bank of Canada reiterated an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. UBS Group dropped their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.